ERBB2 and non-small cell lung carcinoma: Another notable ADC, Trastuzumab emtansine (T-DM1), while showing an ORR of 38.1%, had a limited mPFS of 2.8 months in a focused study of NSCLC patients with HER2 exon 20 insertion mutations (Iwama et al. 2022).